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Abstract 0 The antiserotoninergic activity at the serotonin receptor 
subtype 2 (5-HT2) of seven new 2-aminoethylbenzocyclanones was 
determined with respect to serotonin-induced contractions in rat aorta 
and compared with that of ketanserine ( p 4  = 8.87). Competitive 
antagonism was observed in six compounds (6.72 5 p 4  5 8.12). 
Three-dimensional structures and molecular electrostatic potential dis- 
tributions of ketanserine and 2-aminoethylbenzocyclanones were ana- 
lyzed. Several molecular features correlated with the rank of antisero- 
toninergic activity. In the case of the cyclanone fragment, the rank of 
activity was associated with the degree of planarity of the bicyclic system. 
The steric and electrostatic effects due to the loss of planarity were 
analyzed. In the case of the amino moiety, activity was associated with 
a particular spatial pattern defined by the amino nitrogen, the aromatic 
system, and molecular electrostatic potential minima generated by the 
oxygen atom. 
Substantial evidence for the existence of multiple serotonin 
(5-HT) receptor subtypes has recently been provided.l-6 The 
increasing availability of compounds with selectivity and 
potency for individual 5-HT receptor subtypes has contrib- 
uted to remarkable advances in the understanding of 5-HT 
neurotransmission.24 The identification of 5-HT receptor 
antagonist properties of ketanserine has been a key develop- 
ment in this field. The importance of this compound relates to  
its ability to  discriminate 5-HT, from other 5-HT sites. 
Numerous ketanserine analogues [i.e., setoperone, pirenpe- 
rone, and altanserin (see structure)] have been developed 
with the aim of improving selectivity. Some of these ana- 
logues have been studied with respect to their potential for 
treating anxiety, depression, schizophrenia, and other psy- 
chiatric disorders.6~7 Although ketanserine has shown no 
effect, these compounds bear a benzoylpiperidine residue in 
which a neuroleptic pharmacophore similar to the butyrophe- 
none fragment has been described.8 Moreover, the butyrophe- 
none fragment interacts with various central receptors in- 
volved in behavioral responses. For instance, spiperone, an 
antagonist of D, receptors, has a high affinity for 5-HT, sites.3 
The synthesis and antidopaminergic effects of 2- and 3-ami- 
nomethyltetralones (1 and 2, respectively) have been previ- 
ously reported by our gr0up.7~9-11 These compounds are 
semirigid variants of the general neuroleptic structure 
ArC4N (an aromatic ring + four carbon atoms + an amino 
function). In addition, we have recently described the 5-HTz 
antagonist activity of some 3-aminomethyltetralones 2.12 
Compounds 2a, 2b, and 2c that bear a butyrophenone frag- 
ment acted as inhibitors of the binding of ketanserine to 
5-HT, receptors and showed a degree of activity similar to 
that of methysergide. 
It has been suggested that serotoninergic activity requires 
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generates a particular molecular electrostatic potential 
(MEP) pattern, as well as an aliphatic chain substituted with 
a basic protonable amino group that is placed at a particular 
distance of the aromatic system.13-16 This distance is often 
generated by a two-carbon aliphatic chain. 
We studied 5-HT, antagonistic activity in a series of 
2-aminoethylbenzocyclanones (see structures) which bear 
both the butyrophenone and p-fluorobenzoylpiperidine frag- 
ments. These fragments have aromatic or heteroaromatic 
rings and amino groups separated by two-carbon aliphatic 
chains. The activity of these compounds was measured in rat 
aorta rings stripped of endothelium, a preparation that 
contains 5-HTz receptors.17 To determine complementary 
molecular characteristics associated with antiserotoninergic 
activity, the relationship between activity and structural 
modifications made to cyclanone and amine residues, with 
ketanserine as a reference, was analyzed. 
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Chemistry-The following 2-aminoethylbenzocyclanones, pre- 
pared by two of the authors (J.F. and E.R.) and co-workers,l* were 
studied 2-[&(4-p-fluorobenzoyl)-N-piperidinylethyl)]-l-indanone hy- 
drochloride (3a; mp, 264-266 "C); 2-[P-(N4-(y-p-fluorobenzoyl)- 
propyll-N'-piperazinyl-ethyl]-1-indanone dihydrochloride (3b mp, 
210-214 "C; 2-[~-~4-p-fluorobenzoyI)-N-piperidinilethyll-l-tetralone 
hydrochloride (312; mp, 224-225 "C); 2-[P(N4-(~p-fluorobenzoy1)- 
propyll-N1-piperazinylethyll-l-tetralone dihydrochloride (3d; mp, 
235-238 " 0 ;  2-[~-(N4-o-methoxyphenyl-N1-piperazinylethyl)l- 1- 
tetralonedihydrochloride (3e; mp, 279-281 "C); 2-(p-morpholino- 
ethyl)-1-tetralone hydrochloride (3f; mp, 251-253 "C); 2-[p-(4-p- 
fluorobenzoyl)-N-piperidinylethyll-l-benzosuberone hydrochloride 
(3g; mp, 220-223 "C) (see structures). 
Pharmacology-5-HT, receptor activity was studied in aorta 
preparations from 250-300-g Sprague-Dawley rats (bred at the 
animal facilities, University of Santiago, Spain) that were killed by 
cervical dislocation and carotid arteriotomy. The descending aorta 
was removed, cleaned, stripped of endothelium, and cut into rings of 
4-mm length. Rings were mounted and placed under tension (1300 
mg) in an isolated organ bath containing 20 mL of Krebs solution a t  
37°C that aerated with carbogen (95% 0,, 5% CO,). Following 
equilibration for 60 min, cumulative concentration-effect curves 
were constructed for 5-HT (30 nM to 100 fiM) until two identical 
control curves were obtained by Van Rossum's method.19 Ketanserine 
and the compounds to be tested were incubated for 15 min prior to the 
construction of 5-HT concentration-effed curves. Isometric contrac- 
tions were monitored with a CPOL 0-25-g transducer connected to a 
CELASTER 10s-1 computerized organ bath. Competitive antago- 
nism was quantified by Schild plot analysiszo for three successive 
concentrations of the antagonist, thus allowing calculation of the pA, 
value. Each experiment was performed in four animals. 
Structure-Activity Relationships-The structure of the com- 
pounds tested can be represented as X-CH,-CH,-Y, where X is the 
cyclanone residue and Y the amine residue (Figure 1). These residues 




















Figure 1-The compounds share the general formula X-CH,-CH,-Y: (A) 
fragments X of compounds with fragment Y = Y1; (B) fiagments Y of 
compounds with fragment X = X3. Numbers below the name of each 
compound correspond to p 4  values. Compounds are presented in order 
of decreasing activity. 
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Table I-Competitive Antagonism of 5-HT2 









8.12 k 0.1 1 0.76 
7.30 f 0.05 0.72 
7.45 2 0.52 1.24 
7.35 f 0.85 0.72 
6.72 -+ 0.06 1.13 
6.75 k 0.045 0.75 
8.87 k 0.1 1 0.82 
a a - -
* Inactive. 
were built with the BIOSYM molecular modeling program and fully 
optimized by the AM1 method21 included in the AMPAC program.22 
For each optimized geometry, STO-3G ab initio wave functions were 
calculated with the GAUSSIAN’S0 program.23 These wave functions 
were then used to calculate MEP distributions where MEP minima 
were located with the MEPMIN pr0gram.~4 
In the case of fragments Y (Figure lB), structural fittings ofY2, Y3, 
and Y4 on Y1 were attempted. Structures of fragments Y were built 
and optimized as fragments X. In the case of the reference molecule 
Y1, several starting conformers were considered to avoid local 
minima. Rotations around single bonds were carried out in fragments 
Y2 and Y3 in an attempt to fit the structure of Y1. 
Results and Discussion 
The antiserotoninergic activity of ketanserine and the 
series of 2-aminoethylbenzocyclanones was evaluated with 
respect to 5-HT-induced contractions in rat aorta without 
endothelium. Activity was quantified by Schild plot analysis 
with three different concentrations for each compound. 
Ketanserine and six of the compounds studied (3a, 3b, 3c, 
3d, 3e, and 3g) showed competitive antagonism of 5-HT 
(Table I). Those compounds concentration-dependently 
shifted the 5-HT concentration-response curve to the right, 
with no depression of the maximum effect. In Schild plot 
analysis, slopes did not differ significantly from one, and pA, 
values indicated an important antagonist effect. Compound 3f 
was inactive. 
Structure-activity relationships of cyclanone (X) and 
amine fragments 0 were investigated separately. First, we 
analyzed those compounds with fragment Y constant but with 
variations in X (3a, 312, 3g and ketanserine; Figure lA), 
searching for molecular properties to explain the order of 
activity observed: X1 > X2 > X3 > X4. Analyses were 
performed considering the optimized geometries and the MEP 
distributions of these fragments. Several correlations be- 
tween molecular characteristics and the degree of activity 
were found. First of all, the optimized geometries of the X 
fragments indicated that the structure X1 is completely 
planar (Figure 2A). The same was true for X 2  when the 
hydrogens of its five-member ring were discarded (Figure 2B). 
On the other hand, the six-member ring of X3 showed 
significant deviations from planarity: there is a carbon atom 
placed 0.58 A from the plane of the aromatic ring. The 
seven-member ring in X4 presented the largest deviation 
from planarity (Figure 2D). After analyzing several low- 
energy conformations of this ring, we took the most planar of 
them. In spite of this, there are atoms far from the plane 
defined by the aromatic system (the most extreme case is a 
carbon atom placed at 1.85 A). Furthermore, in X1 (present in 
ketanserine, the most active molecule) and X 2 ,  the deepest 
MEP minima (generated by lone pairs of an oxygen atom) are 
located in the molecular plane (Figures 2A and ZB), whereas 
the oxygen in X3 generates minima at 0.08 and 0.18 A from 
the molecular plane (Figure 2C). The MEP minima generated 
by the oxygen of X4 are far from the plane (0.66 and 1.12 A). 
Figure 2-MEP maps of fragments X on a plane perpendicular to the aromatic ring. The plane contains the MEP minima generated by the carbonyl 
group vicinal to the ring: (A) X1; (B) X2; (C) X3; (D) X4. 
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Figure &Structural superposition of the fragments Y showing distances 
between MEP minima generated by the oxygen atoms (A) Y1 versus Y2; 
(B) Y1 versus Y3; (C) Y1 versus Y4. 
Another aspect of MEP distribution correlating with activity 
related to the symmetry of this distribution with reference to 
the aromatic ring. MEP distributions of X1 and X 2  are totally 
symmetrical, that of X3 is slightly asymmetrical, and that of 
X4 is markedly asymmetrical. 
Secondly, we analyzed those compounds with fragment X 
constant but with variations in Y (3c, 3d, 3e and 3f; Figure 
1B) to explain the order of activity observed: Y1 > Y2 > Y3 
> Y4. Given the conformational degrees of freedom of these 
molecules, flexible structural fitting of Y2, Y3, and Y4 on Y1 
was attempted (Figures 3A-3C). The three fittings were 
executed overlapping first the six-member nitrogen- 
containing rings. Thereafter, coincidence in the same plane 
was achieved for the aromatic rings present in Y1, Y2, andY3 
by rotations around single bonds of Y2 and Y3 (Figures 3A 
and 3B). Although it is possible to place the three phenyl 
groups in a common plane they become closer in the case of 
Y2 and Y1 (Figure 3A 1 A between the center of the rings) 
than in the case of Y3 and Y1 (Figure 3B; 2.2 A between the 
center of the rings). The absence of phenyl group in Y4 could 
be related to the lack of activity of the corresponding com- 
pound. The last aspect that was considered in this set of 
fittings is the proximity between the oxygen-generated MEP 
minima (obtained with MEPMIN as described above). In the 
case of fragment Y3 the methoxy group was rotated around 
the C-0  single bond with the aim of bringing the MEP minima 
as close as possible. In the fitting between Y2 and Y1, the 
distance between minima is 0.3 A (Figure 3A). In the case of 
Y3 versus Y1, this distance is at least 1 A (Figure 3B). MEP 
minima generated by the lone pairs of the oxygen atom of Y4 
cannot be located <2.5 A from the minima generated by the 
oxygen of Y1 (Figure 3C). The ranking of activities of the 
compounds agreed with the ranking of proximities of the 
phenyl groups and the oxygen-generated MEP minima versus 
the same groups in the more active compound (containing the 
fragment Yl). 
In conclusion, six of the seven 2-aminomethylcyclanones 
tested proved to be antagonists of 5-HT in rat aorta. Com- 
pound 3b presented an activity comparable to that of ketan- 
serine. The structural requirements for the cyclanone frag- 
ment to contribute to activity appeared to be related to the 
planarity of the molecule, the symmetry of the MEP distri- 
bution, and the location of main MEP minima in the molec- 
ular plane. In the amino fragments, the 5-HT, antiserotonin- 
ergic activity appeared to be related to the presence of both an 
aromatic ring and a MEP minimum generated by an hetero- 
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